Concerns Rise Over Generic Drug Supply Shortages in the U.S.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy VTRS?
Source: seekingalpha
- Supply Chain Risk: The ongoing situation in the Strait of Hormuz raises concerns about potential shortages of generic drugs, which account for 90% of U.S. prescriptions, with nearly half supplied by India, impacting patient access to medications.
- Raw Material Dependency: Many prescription drugs rely on petroleum-based raw materials, and the Strait of Hormuz, responsible for about 20% of global oil transport, faces restricted tanker movement, potentially leading to shortages in production inputs.
- Cost Increase Warning: William Feldman, a professor at UCLA, highlights that the thin profit margins of generic drugs make them vulnerable to rising production costs due to escalating conflicts, which could ultimately affect drug prices and availability for patients.
- Market Signals: While current inventories can last 30 to 60 days, early signs indicate rising air cargo rates from India and increasing concerns among manufacturers about inventory pressures, suggesting potential supply issues in the near future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VTRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VTRS
Wall Street analysts forecast VTRS stock price to fall
4 Analyst Rating
2 Buy
1 Hold
1 Sell
Hold
Current: 13.510
Low
10.00
Averages
13.25
High
16.00
Current: 13.510
Low
10.00
Averages
13.25
High
16.00
About VTRS
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Concerns Rise Over Generic Drug Supply Shortages in the U.S.
- Supply Chain Risk: The ongoing situation in the Strait of Hormuz raises concerns about potential shortages of generic drugs, which account for 90% of U.S. prescriptions, with nearly half supplied by India, impacting patient access to medications.
- Raw Material Dependency: Many prescription drugs rely on petroleum-based raw materials, and the Strait of Hormuz, responsible for about 20% of global oil transport, faces restricted tanker movement, potentially leading to shortages in production inputs.
- Cost Increase Warning: William Feldman, a professor at UCLA, highlights that the thin profit margins of generic drugs make them vulnerable to rising production costs due to escalating conflicts, which could ultimately affect drug prices and availability for patients.
- Market Signals: While current inventories can last 30 to 60 days, early signs indicate rising air cargo rates from India and increasing concerns among manufacturers about inventory pressures, suggesting potential supply issues in the near future.
See More
Market Capitalization Comparison: West Pharmaceutical vs. Viatris
- Market Cap Overview: West Pharmaceutical (WST) has a market capitalization of $17.16 billion compared to Viatris (VTRS) at $16.07 billion, highlighting the relative size difference that influences investor choices and capital flows.
- Investor Misconception: Many novice investors mistakenly believe that a higher stock price indicates greater company value, but market capitalization provides a more accurate comparison of company worth, aiding investors in making informed decisions.
- Market Impact: Market capitalization determines a company's size tier among peers, influencing which mutual funds and ETFs are willing to hold these stocks, particularly as large funds tend to favor companies with market caps exceeding $10 billion.
- Stock Performance: At Thursday's close, WST's stock fell approximately 3%, while VTRS declined about 1.2%, reflecting differing market reactions to the short-term performance of the two companies.
See More
Viatris Settles with Henrietta Lacks Estate Over Cell Use Allegations
- Settlement Reached: Viatris has settled with the estate of Henrietta Lacks to resolve allegations of using her cancer cells without permission, indicating the company's proactive approach to mitigate legal disputes and avoid further litigation.
- Lawsuit Concluded: The settlement resolves the case with prejudice, meaning similar claims cannot be refiled, which reduces future legal risks and protects the company's reputation in the healthcare sector.
- Family Satisfaction: A lawyer for Lacks' estate expressed that the family is pleased with the resolution, reflecting a compromise that may serve as a precedent for future settlements with other healthcare companies.
- Biomedical Research Impact: Since 1951, Lacks' cell line has been a cornerstone in biopharma research, and Viatris' settlement may prompt the company to enhance ethical compliance management to maintain its reputation and market position in the industry.
See More
GoodRx Partners with Viatris to Offer Up to 85% Discounts on Medications
- Discount Program Launch: GoodRx has partnered with Viatris to introduce a new program offering up to 85% discounts on 17 brand-name medications, including the cholesterol drug Lipitor, which is expected to significantly reduce patient medication costs.
- Extensive Coverage: The discount program will be available at over 70,000 pharmacies across the U.S., making it easier for patients to access necessary medications, thereby enhancing GoodRx's market position in drug price transparency and accessibility.
- Insurance Patient Benefits: Some Viatris medications will be available on GoodRx for as low as $0–$4 for patients with commercial insurance, a strategy that not only expands GoodRx's user base but may also improve patient adherence to medication regimens.
- Market Response: GoodRx noted that the selected medications already generate significant search volume on its platform, indicating strong market demand for these drugs, which further solidifies GoodRx's influence in the healthcare sector.
See More
GOODRX TEAMS UP WITH VIATRIS TO PROVIDE UP TO 85% DISCOUNTS ON WELL-KNOWN BRAND MEDICATIONS
Partnership Announcement: GoodRx has partnered with Viatris to provide significant savings on established brand medications.
Savings Details: The collaboration offers up to 85% savings for consumers on select medications through GoodRx's platform.
See More
Alphabet and Others Set for Ex-Dividend Dates
- GOOG Ex-Dividend Info: Alphabet Inc will go ex-dividend on March 9, 2026, with a quarterly dividend of $0.21, translating to an approximate yield of 0.07% based on its current stock price of $303.45, suggesting a potential 0.07% drop at market open, which could influence short-term investor decisions.
- CEG Dividend Announcement: Constellation Energy Corp will pay a quarterly dividend of $0.4265 on March 20, 2026, with an expected price drop of 0.13% post-ex-dividend, reflecting the company's efforts in maintaining stable dividends, potentially attracting yield-seeking investors.
- VTRS Dividend Dynamics: Viatris Inc will distribute a quarterly dividend of $0.12 on March 18, 2026, with an anticipated 0.82% decline at market open, indicating the company's ongoing commitment to dividend payments, which may enhance its market appeal.
- Dividend History and Yields: Historical data shows an annualized yield of 0.28% for Alphabet, 0.53% for CEG, and a notable 3.26% for VTRS, providing investors with a basis for assessing future dividend stability, which could impact their investment strategies.
See More
Concerns Rise Over Generic Drug Supply Shortages in the U.S.
- Supply Chain Risk: The ongoing situation in the Strait of Hormuz raises concerns about potential shortages of generic drugs, which account for 90% of U.S. prescriptions, with nearly half supplied by India, impacting patient access to medications.
- Raw Material Dependency: Many prescription drugs rely on petroleum-based raw materials, and the Strait of Hormuz, responsible for about 20% of global oil transport, faces restricted tanker movement, potentially leading to shortages in production inputs.
- Cost Increase Warning: William Feldman, a professor at UCLA, highlights that the thin profit margins of generic drugs make them vulnerable to rising production costs due to escalating conflicts, which could ultimately affect drug prices and availability for patients.
- Market Signals: While current inventories can last 30 to 60 days, early signs indicate rising air cargo rates from India and increasing concerns among manufacturers about inventory pressures, suggesting potential supply issues in the near future.
See More
Market Capitalization Comparison: West Pharmaceutical vs. Viatris
- Market Cap Overview: West Pharmaceutical (WST) has a market capitalization of $17.16 billion compared to Viatris (VTRS) at $16.07 billion, highlighting the relative size difference that influences investor choices and capital flows.
- Investor Misconception: Many novice investors mistakenly believe that a higher stock price indicates greater company value, but market capitalization provides a more accurate comparison of company worth, aiding investors in making informed decisions.
- Market Impact: Market capitalization determines a company's size tier among peers, influencing which mutual funds and ETFs are willing to hold these stocks, particularly as large funds tend to favor companies with market caps exceeding $10 billion.
- Stock Performance: At Thursday's close, WST's stock fell approximately 3%, while VTRS declined about 1.2%, reflecting differing market reactions to the short-term performance of the two companies.
See More
Viatris Settles with Henrietta Lacks Estate Over Cell Use Allegations
- Settlement Reached: Viatris has settled with the estate of Henrietta Lacks to resolve allegations of using her cancer cells without permission, indicating the company's proactive approach to mitigate legal disputes and avoid further litigation.
- Lawsuit Concluded: The settlement resolves the case with prejudice, meaning similar claims cannot be refiled, which reduces future legal risks and protects the company's reputation in the healthcare sector.
- Family Satisfaction: A lawyer for Lacks' estate expressed that the family is pleased with the resolution, reflecting a compromise that may serve as a precedent for future settlements with other healthcare companies.
- Biomedical Research Impact: Since 1951, Lacks' cell line has been a cornerstone in biopharma research, and Viatris' settlement may prompt the company to enhance ethical compliance management to maintain its reputation and market position in the industry.
See More
GoodRx Partners with Viatris to Offer Up to 85% Discounts on Medications
- Discount Program Launch: GoodRx has partnered with Viatris to introduce a new program offering up to 85% discounts on 17 brand-name medications, including the cholesterol drug Lipitor, which is expected to significantly reduce patient medication costs.
- Extensive Coverage: The discount program will be available at over 70,000 pharmacies across the U.S., making it easier for patients to access necessary medications, thereby enhancing GoodRx's market position in drug price transparency and accessibility.
- Insurance Patient Benefits: Some Viatris medications will be available on GoodRx for as low as $0–$4 for patients with commercial insurance, a strategy that not only expands GoodRx's user base but may also improve patient adherence to medication regimens.
- Market Response: GoodRx noted that the selected medications already generate significant search volume on its platform, indicating strong market demand for these drugs, which further solidifies GoodRx's influence in the healthcare sector.
See More
GOODRX TEAMS UP WITH VIATRIS TO PROVIDE UP TO 85% DISCOUNTS ON WELL-KNOWN BRAND MEDICATIONS
Partnership Announcement: GoodRx has partnered with Viatris to provide significant savings on established brand medications.
Savings Details: The collaboration offers up to 85% savings for consumers on select medications through GoodRx's platform.
See More
Alphabet and Others Set for Ex-Dividend Dates
- GOOG Ex-Dividend Info: Alphabet Inc will go ex-dividend on March 9, 2026, with a quarterly dividend of $0.21, translating to an approximate yield of 0.07% based on its current stock price of $303.45, suggesting a potential 0.07% drop at market open, which could influence short-term investor decisions.
- CEG Dividend Announcement: Constellation Energy Corp will pay a quarterly dividend of $0.4265 on March 20, 2026, with an expected price drop of 0.13% post-ex-dividend, reflecting the company's efforts in maintaining stable dividends, potentially attracting yield-seeking investors.
- VTRS Dividend Dynamics: Viatris Inc will distribute a quarterly dividend of $0.12 on March 18, 2026, with an anticipated 0.82% decline at market open, indicating the company's ongoing commitment to dividend payments, which may enhance its market appeal.
- Dividend History and Yields: Historical data shows an annualized yield of 0.28% for Alphabet, 0.53% for CEG, and a notable 3.26% for VTRS, providing investors with a basis for assessing future dividend stability, which could impact their investment strategies.
See More
